التفاصيل البيبلوغرافية
| العنوان: |
Exploring the views of infection consultants in England on a novel delinked funding model for antimicrobials: the SMASH study |
| المؤلفون: |
Ioannis Baltas, Mark Gilchrist, Eirini Koutoumanou, Malick M Gibani, James E Meiring, Akaninyene Otu, David Hettle, Ameeka Thompson, James Price, Anna Crepet, Abolaji Atomode, Timothy Crocker-Buque, Dimitrios Spinos, Hudson Guyver, Matija Tausan, Donald Somasunderam, Maxwell Thoburn, Cathleen Chan, Helen Umpleby, Bethany Sharp, Callum Chivers, Devan Suresh Vaghela, Ronak J Shah, Jonathan Foster, Amy Hume, Christopher Smith, Ammara Asif, Dimitrios Mermerelis, Mohammad Abbas Reza, Dominic A Haigh, Thomas Lamb, Loucia Karatzia, Alexandra Bramley, Nikhil Kadam, Konstantinos Kavallieros, Veronica Garcia-Arias, Jane Democratis, Claire S Waddington, Luke SP Moore, Alexander M Aiken |
| سنة النشر: |
2023 |
| المجموعة: |
University of Sussex (US): Figshare |
| مصطلحات موضوعية: |
Antimicrobial Resistance, Vaccine Related, Biodefense, Infectious Diseases, Prevention, Emerging Infectious Diseases, Infection, 3 Good Health and Well Being |
| الوصف: |
Objectives A novel ‘subscription-type’ funding model was launched in England in July 2022 for ceftazidime/avibactam and cefiderocol. We explored the views of infection consultants on important aspects of the delinked antimicrobial funding model. Methods An online survey was sent to all infection consultants in NHS acute hospitals in England. Results The response rate was 31.2% (235/753). Most consultants agreed the model is a welcome development (69.8%, 164/235), will improve treatment of drug-resistant infections (68.5%, 161/235) and will stimulate research and development of new antimicrobials (57.9%, 136/235). Consultants disagreed that the model would lead to reduced carbapenem use and reported increased use of cefiderocol post-implementation. The presence of an antimicrobial pharmacy team, requirement for preauthorization by infection specialists, antimicrobial stewardship ward rounds and education of infection specialists were considered the most effective antimicrobial stewardship interventions. Under the new model, 42.1% (99/235) of consultants would use these antimicrobials empirically, if risk factors for antimicrobial resistance were present (previous infection, colonization, treatment failure with carbapenems, ward outbreak, recent admission to a high-prevalence setting). Significantly higher insurance and diversity values were given to model antimicrobials compared with established treatments for carbapenem-resistant infections, while meropenem recorded the highest enablement value. Use of both ‘subscription-type’ model drugs for a wide range of infection sites was reported. Respondents prioritized ceftazidime/avibactam for infections by bacteria producing OXA-48 and KPC and cefiderocol for those producing MBLs and infections with Stenotrophomonas maltophilia , Acinetobacter spp. and Burkholderia cepacia . Conclusions The ‘subscription-type’ model was viewed favourably by infection consultants in England. |
| نوع الوثيقة: |
article in journal/newspaper |
| اللغة: |
unknown |
| العلاقة: |
10779/uos.23925963.v1; https://figshare.com/articles/journal_contribution/Exploring_the_views_of_infection_consultants_in_England_on_a_novel_delinked_funding_model_for_antimicrobials_the_SMASH_study/23925963Test |
| الإتاحة: |
https://figshare.com/articles/journal_contribution/Exploring_the_views_of_infection_consultants_in_England_on_a_novel_delinked_funding_model_for_antimicrobials_the_SMASH_study/23925963Test |
| حقوق: |
CC BY 4.0 |
| رقم الانضمام: |
edsbas.C8167F28 |
| قاعدة البيانات: |
BASE |
